Best treatments for non-small-cell lung carcinoma
44 products may treat non-small-cell lung carcinoma, spanning FDA drug classes such as vascular endothelial growth factor inhibitor, programmed death receptor-1 blocking antibody, kinase inhibitor. The current highest-rated option is alymsys. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 44 drugs we list for non-small-cell lung carcinoma, 5 are available as lower-cost generics, spanning classes such as vascular endothelial growth factor inhibitor, programmed death receptor-1 blocking antibody, kinase inhibitor. 20 of 44 carry a safety score, from 60 to 72 out of 100. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for non-small-cell lung carcinoma — so confirm the right choice with your prescriber.
Understanding non-small-cell lung carcinoma
Non-small cell lung cancer (NSCLC) is a type of cancer that forms in the tissues of the lung. It is the most common type of lung cancer; the American Cancer Society notes that about 80% to 85% of lung cancers are NSCLC. Its main subtypes, based on how the cells look under a microscope, are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Early NSCLC often causes no signs or symptoms and is sometimes found on a chest X-ray done for another reason. When symptoms do appear, they may include a cough that does not go away or gets worse, chest discomfort or pain, trouble breathing, wheezing, hoarseness, coughing up blood, loss of appetite, unexplained weight loss, and feeling very tired. Doctors diagnose and stage NSCLC using a medical history, physical exam, imaging such as chest X-rays and CT scans, laboratory tests, and a biopsy of lung tissue or fluid. Molecular (biomarker) testing of the tumor looks for specific gene changes, such as EGFR and ALK, to help guide treatment. Management depends on the type and stage of the cancer. This is general information, not medical advice.
First-line treatment
There is no single first-line treatment for NSCLC. According to the American Cancer Society, treatment options are based mainly on the stage (extent) of the cancer, but other factors—such as a person's overall health and lung function, and certain traits of the cancer itself, including gene mutations (for example EGFR, ALK, KRAS, ROS1, BRAF) and PD-L1 protein levels—are also important. This means staging and tumor biomarker/molecular testing are done before a plan is set. Depending on these results, the categories of options described by NCI and the American Cancer Society include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Treatment is highly individualized, and planning often requires input from an oncology team—for example, a medical oncologist, radiation oncologist, and thoracic surgeon working together. The specific plan is determined by an oncology team for each patient.
Top-rated picks for non-small-cell lung carcinoma: 1. Alymsys · 2. Avastin · 3. Emrelis
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Injectable | — | No data | — | View → | |
| 2 | 72/100 | Prescription | Injectable | Vascular Endothelial Growth Factor Inhibitor | No data | — | View → | |
| 3 | 72/100 | Prescription | Injectable | — | No data | — | View → | |
| 4 | 72/100 | Prescription | Tablet | — | No data | — | View → | |
| 5 | 72/100 | Prescription | Tablet | — | No data | — | View → | |
| 6 | 72/100 | Prescription | Injectable | Programmed Death Receptor-1 Blocking Antibody | No data | — | View → | |
| 7 | 72/100 | Prescription | Tablet | — | No data | — | View → | |
| 8 | 72/100 | Prescription | Injectable | — | No data | — | View → | |
| 9 | 72/100 | Prescription | Injectable | Programmed Death Receptor-1 Blocking Antibody | No data | — | View → | |
| 10 | 72/100 | Prescription | Injectable | — | No data | — | View → |
Narrow by drug class
Explore the class hubs: kinase inhibitor · topoisomerase inhibitor · microtubule inhibitor · programmed death receptor-1 blocking antibody
Full ranking · 44 treatments
alymsys
PrescriptionFDA-sourced
Alymsys (Bevacizumab-Maly) is a medication used to treat Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma.
Price varies
avastin
PrescriptionFDA-sourced
Avastin (Bevacizumab) is a vascular endothelial growth factor inhibitor used to treat Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma.
Price varies
emrelis
PrescriptionFDA-sourced
Emrelis (Telisotuzumab Vedotin-Tllv) is a medication used to treat Non-Small-Cell Lung Carcinoma.
Price varies
gilotrif
PrescriptionFDA-sourced
Gilotrif (Afatinib Dimaleate) is a medication used to treat Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma.
Price varies
hernexeos
PrescriptionFDA-sourced
Hernexeos (Zongertinib) is a medication used to treat Non-Small-Cell Lung Carcinoma.
Price varies
keytruda
PrescriptionFDA-sourced
Keytruda (Pembrolizumab) is a programmed death receptor-1 blocking antibody used to treat Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma.
Price varies
- Lumakras
- Mvasi
- Opdivo
- Portrazza
- Rozlytrek
- Tecentriq
- Mekinist
- Pemfexy
- Tabrecta
- Tagrisso
- Taxotere
- Hycamtin
- Camptosar
- Vizimpro
- Alecensa
- Alimta
- Alunbrig
- Avzivi
- Axtle
- Docivyx
- Droxia
- Gavreto
- Hydrea
- Ibtrozi
- Inlexzo
- Irinotecan Hydrochloride
- Jobevne
- Krazati
- Onivyde
- Pemetrexed for Injection
- Retevmo
- Rybrevant
- Siklos
- Topotecan Hydrochloride
- Vegzelma
- Xalkori
- Xromi
- Zegfrovy
Frequently asked
- What treats non-small-cell lung carcinoma?
- Our catalog lists 44 products that may treat non-small-cell lung carcinoma, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is alymsys.
- What is the best-rated treatment for non-small-cell lung carcinoma?
- By our independent recall-safety rating — not an efficacy measure — alymsys ranks highest among the products we list for non-small-cell lung carcinoma. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat non-small-cell lung carcinoma?
- Treatments for non-small-cell lung carcinoma span FDA drug classes including vascular endothelial growth factor inhibitor, programmed death receptor-1 blocking antibody, kinase inhibitor, microtubule inhibitor, topoisomerase inhibitor. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.
Sources
The clinical overview above is written from these authoritative public-health and medical-society sources, independently reviewed against each.